Merck HPV vaccine for men approved in China
Merck & Co's human papillomavirus (HPV) vaccine, Gardasil, has received approval from China's medical products administration for men aged 9-26 years.
Gardasil, a key product for Merck alongside its blockbuster cancer treatment Keytruda, has been a significant growth driver internationally, particularly in China.
In October, Merck said weak sales in China of its Gardasil vaccine, used to prevent HPV, were likely to continue into 2025 amid weak demand among women.
Medical Dialogues team had earlier reported that Merck had received approval from the UK's Medicines and Healthcare products Regulatory Agency for its therapy, sotatercept, to treat a rare lung condition. Sotatercept gained U.S. approval in March 2024 and is sold under the brand name Winrevair. It is also approved in European Union and 30 other markets.
